Obesity-associated digestive cancers: A review of mechanisms and interventions

Tumor Biology

Volumn 39, Issue 3, 2017, Pages 1-11

  Zheng, Jiachen ^a   Zhao, Ming ^a   Li, Jiahui ^a   Lou, Guoying ^a   Yuan, Yanyan ^a   Bu, Shizhong ^a   Xi, Yang ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

Digestive cancers; Inflammation; Mechanisms of cancers; Obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BETA CATENIN; COLLAGENASE 3; CYCLOOXYGENASE 2; INSULIN; INTERLEUKIN 6; K RAS PROTEIN; LEPTIN; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN;

CALORIC RESTRICTION; CARCINOGENESIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; DIET; DIGESTIVE SYSTEM CANCER; ESOPHAGEAL ADENOCARCINOMA; GENE MUTATION; HUMAN; LIVER CANCER; NONHUMAN; OBESITY; PANCREAS CANCER; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; COLORECTAL NEOPLASMS; COMPLICATION; DIGESTIVE SYSTEM NEOPLASMS; ENERGY METABOLISM; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; GENETICS; PATHOLOGY; RISK FACTOR;

COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; ENERGY METABOLISM; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; OBESITY; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 85016923695     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317695020     Document Type: Review

References (147)

1. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569–578.
2. Wolin KY, Carson K and Colditz GA. Obesity and cancer. Oncologist 2010; 15: 556–565.
3. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638.
4. Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384: 755–765.
5. Lyman GH and Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 2013; 10: 451–459.
6. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30: 1553–1561.
7. Nock NL, Thompson CL, Tucker TC, et al. Associations between obesity and changes in adult BMI over time and colon cancer risk. Obesity 2008; 16: 1099–1104.
8. Broaddus E, Topham A and Singh AD. Survival with retinoblastoma in the USA: 1975–2004. Br J Ophthalmol 2009; 93: 24–27.
9. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191–198.
10. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci 2010; 118: 315–332.
11. Gallagher EJ and LeRoith D. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes 2013; 20: 485–494.
12. Gallagher EJ and LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36(Suppl. 2): S233–S239.
13. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114: 63–70.
14. Renehan AG, Roberts DL, Dive C, et al. Cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem 2008; 114: 71–83.
15. Doyle SL, Donohoe CL, Finn SP, et al. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. Am J Gastroenterol 2012; 107: 196–204.
16. Chan AT and Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 138: 2029–2043.e10.
17. Guo YS, Narayan S, Yallampalli C, et al. Characterization of insulin like growth factor I receptors in human colon cancer. Gastroenterology 1992; 102: 1101–1108.
18. Francois F, Roper J, Goodman AJ, et al. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut 2008; 57: 16–24.
19. Sennello JA, Fayad R, Morris AM, et al. Regulation of t cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 2005; 146: 2157–2164.
20. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class a scavenger receptor expression in human monocytederived macrophages. Circulation 2001; 103: 1057–1063.
21. Gialamas SP, Petridou ET, Tseleni-Balafouta S, et al. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 2011; 60: 1530–1538.
22. Kai H, Kitadai Y, Kodama M, et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 2005; 25: 709–713.
23. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197–208.
24. Yu H, Pardoll D and Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798–809.
25. Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of MIR-21 and MIR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493–506.
26. Klaus A and Birchmeier W. WNT signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387–398.
27. Morikawa T, Kuchiba A, Lochhead P, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with beta-catenin (CTNNB1) status. Cancer Res 2013; 73: 1600–1610.
28. Philip B, Roland CL, Daniluk J, et al. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 2013; 145: 1449–1458.
29. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 1218–1249.
30. Dannenberg AJ and Subbaramaiah K. Targeting cyclooxygenase- 2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4: 431–436.
31. Fan Y, Gan Y, Shen Y, et al. Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production. Oncotarget 2015; 6: 16120–16134.
32. Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002; 967: 379–388.
33. Pohl H, Sirovich B and Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010; 19: 1468–1470.
34. Edgren G, Adami HO, Weiderpass E, et al. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013; 62: 1406–1414.
35. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.
36. Kubo A and Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 872–878.
37. Hampel H, Abraham NS and El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199–211.
38. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett’s esophagus. Gastroenterology 2007; 133: 403–411.
39. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006; 130: 639–649.
40. Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007; 132: 883–889.
41. Kahrilas PJ. The role of hiatus hernia in GERD. Yale J Biol Med 1999; 72: 101–111.
42. Frezza EE, Ikramuddin S, Gourash W, et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc 2002; 16: 1027–1031.
43. Stein HJ and Siewert JR. Barrett’s esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management. Dysphagia 1993; 8: 276–288.
44. Reid BJ, Sanchez CA, Blount PL, et al. Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119–129.
45. Levine DM, Ek WE, Zhang R, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet 2013; 45: 1487–1493.
46. De Groot NL, Burgerhart JS, Van De Meeberg PC, et al. Systematic review: The effects of conservative and surgical treatment for obesity on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2009; 30: 1091–1102.
47. Alexandre L, Long E and Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol 2014; 5: 534–549.
48. Nam SY, Choi IJ, Ryu KH, et al. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women. Gastroenterology 2010; 139: 1902–1911.
49. Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrett’s esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2013; 11: 934–943.
50. You T, Yang R, Lyles MF, et al. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005; 288: E741–E747.
51. Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010; 59: 1259–1264.
52. Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23: 843–852.
53. Anandavadivelan P, Brismar TB, Nilsson M, et al. Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr 2016; 35: 724–730.
54. Kamangar F, Dores GM and Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137–2150.
55. Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer 2009; 45: 2867–2873.
56. Armstrong RW and Borman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978–1992. Int J Epidemiol 1996; 25: 941–947.
57. Crew KD and Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354–362.
58. Allum WH, Powell DJ, McConkey CC, et al. Gastric cancer: a 25-year review. Br J Surg 1989; 76: 535–540.
59. Lagergren J, Bergstrom R and Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883–890.
60. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 150–155.
61. Helicobacter Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347–353.
62. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999; 397: 176–180.
63. Kuriyama S, Tsubono Y, Hozawa A, et al. Obesity and risk of cancer in Japan. Int J Cancer 2005; 113: 148–157.
64. Ericksen RE, Rose S, Westphalen CB, et al. Obesity accelerates Helicobacter felis-induced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. Gut 2014; 63: 385–394.
65. Jackson CB, Judd LM, Menheniott TR, et al. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J Pathol 2007; 213: 140–151.
66. Inagaki-Ohara K, Mayuzumi H, Kato S, et al. Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice. Oncogene 2014; 33: 74–84.
67. Garofalo C and Surmacz E. Leptin and cancer. J Cell Physiol 2006; 207: 12–22.
68. Kuroda T, Kitadai Y, Tanaka S, et al. Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res 2005; 11: 7629–7636.
69. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718–15723.
70. Bultman SJ. The microbiome and its potential as a cancer preventive intervention. Semin Oncol 2016; 43: 97–106.
71. Savini I, Catani MV, Evangelista D, et al. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int J Mol Sci 2013; 14: 10497–10538.
72. Verweij CL and Gringhuis SI. Oxidants and tyrosine phosphorylation: role of acute and chronic oxidative stress in Tand B-lymphocyte signaling. Antioxid Redox Signal 2002; 4: 543–551.
73. Bianchini F, Kaaks R and Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565–574.
74. Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Int Med 1995; 122: 327–334.
75. Martinez ME, Giovannucci E, Spiegelman D, et al. Leisuretime physical activity, body size, and colon cancer in women. Nurses’ Health Study Research Group. J National Cancer Inst 1997; 89: 948–955.
76. Park Y, Hunter DJ, Spiegelman D, et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005; 294: 2849–2857.
77. Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56: 1010–1013.
78. Rizzo A, Pallone F, Monteleone G, et al. Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol 2011; 17: 3092–3100.
79. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995; 6: 164–179.
80. Giovannucci E. Insulin insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109S–3120S.
81. Attoub S, Noe V, Pirola L, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 2000; 14: 2329–2338.
82. Koda M, Sulkowska M, Kanczuga-Koda L, et al. Overexpression of the obesity hormone leptin in human colorectal cancer. J Clin Pathol 2007; 60: 902–906.
83. Mojiminiyi OA and Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 2007; 67: 215–225.
84. Baragli A, Lanfranco F, Allasia S, et al. Neuroendocrine and metabolic activities of ghrelin gene products. Peptides 2011; 32: 2323–2332.
85. Jeffery PL, Herington AC and Chopin LK. The potential autocrine/paracrine roles of ghrelin and its receptor in hormone- dependent cancer. Cytokine Growth Factor Rev 2003; 14: 113–122.
86. Warolin J, Coenen KR, Kantor JL, et al. The relationship of oxidative stress, adiposity and metabolic risk factors in healthy Black and White American youth. Pediatr Obes 2014; 9: 43–52.
87. Wang Z, Li S, Cao Y, et al. Oxidative stress and carbonyl lesions in ulcerative colitis and associated colorectal cancer. Oxid Med Cell Longev 2016; 2016: 9875298.
88. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Bio 2007; 39: 44–84.
89. Riondino S, Roselli M, Palmirotta R, et al. colorectal cancer: role of adipokines in tumor initiation and progression. World J Gastroenterol 2014; 20: 5177–5190.
90. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5–S16.
91. Llovet JM, Burroughs A and Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–1917.
92. Blonski W, Kotlyar DS and Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3603–3615.
93. Rui R, Lou J, Zou L, et al. Excess body mass index and risk of liver cancer: a nonlinear dose-response meta-analysis of prospective studies. PLoS ONE 2012; 7: e44522.
94. McKillop IH, Moran DM, Jin X, et al. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006; 136: 125–135.
95. Vilchez V, Turcios L, Marti F, et al. Targeting Wnt/β- catenin pathway in hepatocellular carcinoma treatment. World J Gastroenterol 2016; 22: 823–832.
96. Bruix J. Usefulness of the molecular profile in the diagnosis, prognosis and treatment of hepatocellular carcinoma. Gastroentero Hepatol 2014; 37(Suppl. 2): 81–89.
97. Barash H, R Gross E, Edrei Y, et al. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A 2010; 107: 2207–2212.
98. Severi T, van Malenstein H, Verslype C, et al. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010; 31: 1409–1420.
99. Stickel F and Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303–1307.
100. Hai S, Kubo S, Shuto T, et al. Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases. Surg Today 2006; 36: 390–394.
101. Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579–591.
102. Calvisi DF., Dr. Jekyll and Mr. Hyde: a paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancer. Hepatology 2011; 54: 9–12.
103. Hong F, Jaruga B, Kim WH, et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J Clin Invest 2002; 110: 1503–1513.
104. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12: 492–499.
105. Malato Y, Naqvi S, Schurmann N, et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest 2011; 121: 4850–4860.
106. Yang S, Lin HZ, Hwang J, et al. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001; 61: 5016–5023.
107. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
108. Lin QJ, Yang F, Jin C, et al. Current status and progress of pancreatic cancer in china. World J Gastroenterol 2015; 21: 7988–8003.
109. Eberle CA, Bracci PM and Holly EA. Anthropometric factors and pancreatic cancer in a population-based casecontrol study in the San Francisco bay area. Cancer Causes Control 2005; 16: 1235–1244.
110. Larsson SC, Permert J, Hakansson N, et al. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population- based cohorts. Br J Cancer 2005; 93: 1310–1315.
111. Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010; 170: 791–802.
112. McCarthy MI. Genomics, type 2 diabetes, and obesity. New Engl J Med 2010; 363: 2339–2350.
113. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889–894.
114. Tang H, Dong X, Hassan M, et al. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 779–792.
115. Petersen GM, Amundadottir L, Fuchs CS, et al. A genomewide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010; 42: 224–228.
116. Fox CS, Heard-Costa N, Cupples LA, et al. Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K project. BMC Med Genet 2007; 8(Suppl. 1): S18.
117. Steinhilber D, Fischer AS, Metzner J, et al. 5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis. Front Pharmacol 2010; 1: 143.
118. Chakrabarti SK, Wen Y, Dobrian AD, et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab 2011; 300: E175–E187.
119. Lago R, Gomez R, Lago F, et al. Leptin beyond body weight regulation—current concepts concerning its role in immune function and inflammation. Cell Immunol 2008; 252: 139–145.
120. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010; 62: 199–236.
121. Wohlfert EA, Nichols FC, Nevius E, et al. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and immunoregulation: enhancement of regulatory T cells through PPARγ- dependent and -independent mechanisms. J Immunol 2007; 178: 4129–4135.
122. Raso GM, Pacilio M, Esposito E, et al. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol 2002; 137: 799–804.
123. Caldefie-Chezet F, Poulin A, Tridon A, et al. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukocyte Biol 2001; 69: 414–418.
124. Tian Z, Sun R, Wei H, et al. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 2002; 298: 297–302.
125. Douglas JB, Silverman DT, Pollak MN, et al. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010; 19: 2298–2306.
126. Roberts DL, Dive C and Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Ann Rev Med 2010; 61: 301–316.
127. Wolpin BM, Bao Y, Qian ZR, et al. Hyperglycemia, insulin resistance, impaired pancreatic beta-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 2013; 105: 1027–1035.
128. Doi Y, Yashiro M, Yamada N, et al. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Ann Surg Oncol 2012; 19: 2733–2743.
129. Bracci PM. Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinogen 2012; 51: 53–63.
130. Garg SK, Maurer H, Reed K, et al. Cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 2014; 16: 97–110.
131. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674–1685.
132. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.
133. Kourelis TV and Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012; 29: 1314–1327.
134. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304–1305.
135. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482–488.
136. Brown JC, Winters-Stone K, Lee A, et al. Cancer, physical activity, and exercise. Compr Physiol 2012; 2: 2775–2809.
137. Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 2008; 57: 95–101.
138. Sonestedt E, Roos C, Gullberg B, et al. Fat and carbohydrate intake modify the association between genetic variation in the FTO genotype and obesity. Am J Clin Nutr 2009; 90: 1418–1425.
139. Shanmugalingam T, Crawley D, Bosco C, et al. Obesity and cancer: the role of vitamin D. BMC Cancer 2014; 14: 712.
140. O’Brien KD, Brehm BJ, Seeley RJ, et al. Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005; 90: 2244–2249.
141. Hursting SD, Dunlap SM, Ford NA, et al. Calorie restriction and cancer prevention: a mechanistic perspective. Cancer Metab 2013; 1: 10.
142. Hursting SD, Digiovanni J, Dannenberg AJ, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res 2012; 5: 1260–1272.
143. Ruperez AI, Gil A and Aguilera CM. Genetics of oxidative stress in obesity. Int J Mol Sci 2014; 15: 3118–3144.
144. Zhao X, Rezonzew G, Wang D, et al. Diet modulation is an effective complementary agent in preventing and treating breast cancer lung metastasis. Clin Exp Meta 2014; 31: 625–638.
145. Vaiopoulos AG, Marinou K, Christodoulides C, et al. The role of adiponectin in human vascular physiology. Int J Cardiol 2012; 155: 188–193.
146. De Rosa A, Monaco ML, Capasso M, et al. Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects. Eur J Endocrinol 2013; 169: 37–43.
147. Wen JP, Liu CE, Hu YT, et al. Globular adiponectin regulates energy homeostasis through AMP-activated protein kinase-acetyl-CoA carboxylase (AMPK/ACC) pathway in the hypothalamus. Mol Cell Biochem 2010; 344: 109–115.